In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $9.57 for the day, up 3.68% from the previous closing price of $9.23. In other words, the price has increased by $3.68% from its previous closing price. On the day, 5.29 million shares were traded. NTLA stock price reached its highest trading level at $9.92 during the session, while it also had its lowest trading level at $9.285.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 29 ’25 when Bhanji Muna sold 265 shares for $8.50 per share. The transaction valued at 2,252 led to the insider holds 19,203 shares of the business.
Clark Eliana sold 679 shares of NTLA for $6,104 on Mar 04 ’25. The EVP, Chief Technical Officer now owns 95,369 shares after completing the transaction at $8.99 per share. On Mar 04 ’25, another insider, BASTA JAMES, who serves as the EVP, General Counsel of the company, sold 2,572 shares for $8.99 each. As a result, the insider received 23,122 and left with 111,925 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 991289280 and an Enterprise Value of 606799104. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.75 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 13.316 whereas that against EBITDA is -1.143.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.15, which has changed by -0.5822785 over the last 52 weeks, in comparison to a change of 0.11213791 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.18, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 14.78%, while the 200-Day Moving Average is calculated to be -22.09%.
Shares Statistics:
NTLA traded an average of 4.45M shares per day over the past three months and 5117280 shares per day over the past ten days. A total of 103.54M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.95% of the company’s shares, while institutions hold 92.21% stake in the company. Shares short for NTLA as of 1748563200 were 31557488 with a Short Ratio of 7.09, compared to 1745971200 on 28748798. Therefore, it implies a Short% of Shares Outstanding of 31557488 and a Short% of Float of 34.68.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
